BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 11887091)

  • 1. The advancement of cancer chemoprevention by revision of clinical trial strategies.
    Sharma RA
    Panminerva Med; 2002 Mar; 44(1):41-5. PubMed ID: 11887091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk biomarkers and current strategies for cancer chemoprevention.
    Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
    J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer chemopreventive agents-drugs for the 21st century?
    Baer-Dubowska W
    Acta Pol Pharm; 2006; 63(5):369-73. PubMed ID: 17357586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
    Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
    Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in clinical chemoprevention.
    Kelloff GJ; Hawk ET; Karp JE; Crowell JA; Boone CW; Steele VE; Lubet RA; Sigman CC
    Semin Oncol; 1997 Apr; 24(2):241-52. PubMed ID: 9129692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials.
    Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet R; Doody LA
    J Cell Biochem Suppl; 1994; 19():1-9. PubMed ID: 7823579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evidence-based approach to cancer prevention clinical trials.
    Greenwald P; McDonald SS; Anderson DE
    Eur J Cancer Prev; 2002 Aug; 11 Suppl 2():S43-7. PubMed ID: 12570334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer chemoprevention.
    Hong WK; Lippman SM
    J Natl Cancer Inst Monogr; 1995; (17):49-53. PubMed ID: 8573453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part II.
    Moyad MA
    Urol Oncol; 2004; 22(6):472-7. PubMed ID: 15610864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer.
    Kelloff GJ; Sigman CC; Johnson KM; Boone CW; Greenwald P; Crowell JA; Hawk ET; Doody LA
    Cancer Epidemiol Biomarkers Prev; 2000 Feb; 9(2):127-37. PubMed ID: 10698472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part I.
    Moyad MA
    Urol Oncol; 2004; 22(6):466-71. PubMed ID: 15610863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer chemoprevention and cancer preventive vaccines--a call to action: leaders of diverse stakeholder groups present strategies for overcoming multiple barriers to meet an urgent need.
    Herberman RB; Pearce HL; Lippman SM; Pyenson BS; Alberts DS
    Cancer Res; 2006 Dec; 66(24):11540-9. PubMed ID: 17158189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological relevance of adduct detection to the chemoprevention of cancer.
    Sharma RA; Farmer PB
    Clin Cancer Res; 2004 Aug; 10(15):4901-12. PubMed ID: 15297390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing the "risk" of chemoprevention: defining and targeting high risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture.
    Lippman SM; Lee JJ
    Cancer Res; 2006 Mar; 66(6):2893-903. PubMed ID: 16540634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoprevention of second cancers.
    Mayne ST; Cartmel B
    Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2033-7. PubMed ID: 17057027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials.
    Einspahr JG; Alberts DS; Gapstur SM; Bostick RM; Emerson SS; Gerner EW
    Cancer Epidemiol Biomarkers Prev; 1997 Jan; 6(1):37-48. PubMed ID: 8993796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoprevention strategies for prostate cancer.
    Bosland MC; McCormick DL; Melamed J; Walden PD; Zeleniuch-Jacquotte A; Lumey LH
    Eur J Cancer Prev; 2002 Aug; 11 Suppl 2():S18-27. PubMed ID: 12570331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoprevention of breast cancer.
    Castrellon AB; Glück S
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):443-52. PubMed ID: 18366291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.